Ionis Pharmaceuticals Inc. (NASDAQ: IONS) announced that partner Biogen plans to advance diranersen to registrational development following phase 2 study ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE